manilatimes6d
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
ALK will initially focus on bringing neffy® to the markets in Europe and Canada, the world's second and third largest adrenaline autoinjector ("AAI”) markets. In both markets, the product can be added ...
Pharmabiz3d
ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions
ALK licenses rights to adrenaline nasal spray, neffy from ARS Pharma for emergency treatment of allergic reactions: Hørsholm, Denmark Tuesday, November 12, 2024, 12:00 Hrs [IST] ...
FDA seeks to remove ingredient from cold medicines after data shows it does not work
The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...
CNET on MSN5d
Which Decongestants Are Effective? Why the FDA Wants to Pull a Popular Medicine Ingredient
Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...
ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive ...
manilatimes2d
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Revenue: Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product ...
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® (Nasdaq: MIST) today reported financial results for the ...
SouthFlorida Reporter6d
FDA Plans to Ban Ineffective Cold Medicine Ingredient—How It Will Affect You
Phenylephrine, a common ingredient in over-the-counter cold medications like DayQuil, Theraflu, and Sudafed, may soon be ...
PharmiWeb2d
Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments
Tonix, known for its work in developing new treatments for central nervous system (CNS ... and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with ...
Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and provided ...
Woman's World on MSN4d
Does Phenylephrine Work? Effective Alternatives as FDA Moves to Ban Ingredient in OTC Decongestants
Common decongestants may soon be pulled from shelves. The Food and Drug Administration (FDA) announced Wednesday its proposal ...
Row erupts as doctors call to BAN Lemsip because 'it doesn't work' - but some insist it's the ONLY thing that eases a blocked nose
Health experts have argued that UK customers are being hoodwinked by the drug firms behind the 'useless' medicines - which include Sudafed, Lemsip and Beechams.